Beijing Institute of Radiation Medicine, Beijing, 100850, P. R. China.
Stem Cell Res Ther. 2024 Sep 18;15(1):310. doi: 10.1186/s13287-024-03910-1.
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), can undergo erythroid differentiation, offering a potentially invaluable resource for generating large quantities of erythroid cells. However, the majority of erythrocytes derived from hPSCs fail to enucleate compared with those derived from cord blood progenitors, with an unknown molecular basis for this difference. The expression of vimentin (VIM) is retained in erythroid cells differentiated from hPSCs but is absent in mature erythrocytes. Further exploration is required to ascertain whether VIM plays a critical role in enucleation and to elucidate the underlying mechanisms.
In this study, we established a hESC line with reversible vimentin degradation (dTAG-VIM-H9) using the proteolysis-targeting chimera (PROTAC) platform. Various time-course studies, including erythropoiesis from CD34 human umbilical cord blood and three-dimensional (3D) organoid culture from hESCs, morphological analysis, quantitative real-time PCR (qRT-PCR), western blotting, flow cytometry, karyotyping, cytospin, Benzidine-Giemsa staining, immunofluorescence assay, and high-speed cell imaging analysis, were conducted to examine and compare the characteristics of hESCs and those with vimentin degradation, as well as their differentiated erythroid cells.
Vimentin expression diminished during normal erythropoiesis in CD34 cord blood cells, whereas it persisted in erythroid cells differentiated from hESC. Depletion of vimentin using the degradation tag (dTAG) system promotes erythroid enucleation in dTAG-VIM-H9 cells. Nuclear polarization of erythroblasts is elevated by elimination of vimentin.
VIM disappear during the normal maturation of erythroid cells, whereas they are retained in erythroid cells differentiated from hPSCs. We found that retention of vimentin during erythropoiesis impairs erythroid enucleation from hPSCs. Using the PROTAC platform, we validated that vimentin degradation by dTAG accelerates the enucleation rate in dTAG-VIM-H9 cells by enhancing nuclear polarization.
人类多能干细胞(hPSCs),包括人类胚胎干细胞(hESCs)和诱导多能干细胞(hiPSCs),可以进行红细胞分化,为大量生成红细胞提供了潜在的宝贵资源。然而,与源自脐带血祖细胞的红细胞相比,大多数源自 hPSCs 的红细胞不能去核,其分子基础尚不清楚。hPSCs 分化而来的红细胞中仍表达波形蛋白(VIM),而成熟红细胞中则不存在。需要进一步探索 VIM 是否在去核过程中发挥关键作用,并阐明其潜在机制。
本研究利用蛋白水解靶向嵌合体(PROTAC)平台建立了一个 hESC 系,该系可实现波形蛋白的可逆降解(dTAG-VIM-H9)。通过对 CD34 脐带血的红细胞生成、hESC 的三维(3D)类器官培养进行各种时间进程研究、形态分析、实时定量 PCR(qRT-PCR)、Western blot、流式细胞术、核型分析、细胞离心涂片、联苯胺-吉姆萨染色、免疫荧光检测和高速细胞成像分析,来检测和比较 hESC 及其波形蛋白降解的特征,以及它们分化的红细胞。
CD34 脐带血细胞正常红细胞生成过程中 VIM 表达减少,而 hESC 分化的红细胞中则持续存在。使用降解标签(dTAG)系统耗尽 Vimentin 可促进 dTAG-VIM-H9 细胞中的红细胞去核。消除 Vimentin 可提高红细胞母细胞的核极化。
VIM 在红细胞正常成熟过程中消失,而在 hPSC 分化的红细胞中保留。我们发现,在红细胞生成过程中保留 Vimentin 会损害 hPSCs 中红细胞的去核。利用 PROTAC 平台,我们通过增强核极化验证了 dTAG 对 Vimentin 的降解可加速 dTAG-VIM-H9 细胞的去核率。